Clinical trial
Effect of Selective COX-2 Inhibition on Ulcer Healing
NCT00153673 · Chinese University of Hong Kong, Other · Completed
Key facts
| NCT number | NCT00153673 |
|---|---|
| Title | Effect of Selective COX-2 Inhibition on Ulcer Healing |
| Official title | Phase III Study of a Double-Blind Randomized Comparison of Famotidine Plus Celecoxib Versus Dologesics for Gastric Ulcer Healing in Arthritis Patients (NSAID#5A Study) |
| Lead sponsor | Chinese University of Hong Kong, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Gastric Ulcer |
| Intervention type | Drug |
| Interventions | celecoxib, Dologesics |
| Enrollment | 200 |
| Start date | Feb 1, 2001 |
| Primary completion | Dec 28, 2016 |
| Completion | Apr 12, 2017 |
| First posted | Sep 12, 2005 |
| Last update posted | Apr 21, 2017 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: